India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
This article was originally published in The Pink Sheet Daily
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
You may also be interested in...
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules
MUMBAI - Hopes of a novel drug to treat smoking-induced lung disease were dashed after India's Glenmark Pharma and its U.S.-based research partner Forest Labs announced that the compound under development in Phase IIb human trials failed to meet efficacy endpoints
MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug